Treatment of hypertension in diabetes mellitus

Current Hypertension Reports

Volumn 2, Issue 3, 2000, Pages 335-342

  De La Sierra, Alejandro ^a   Ruilope, Luis Miguel ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ARTERIOSCLEROSIS; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; KIDNEY DISEASES; MYOCARDIAL INFARCTION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 0034201346     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0018-y     Document Type: Article

References (38)

1. Epstein M, Sowers J: Diabetes mellitus and hypertension. Hypertension 1992, 19: 403-418.
2. The National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994, 23: 145-158.
3. Mogensen CE: Management of the diabetic patient with elevated blood pressure and renal disease. Early screening and treatment programs: albuminuria and blood pressure. In Hypertension, Pathophysiology, Diagnosis, and Management. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995: 2336-2365.
4. Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 1995, 26: 869-879.
5. Standley PR, Ali S, Bapna C, Sowers JR: Increased platelet cytosolic calcium responses to low density lipoprotein in type II diabetes with and without hypertension. Am J Hypertens 1993, 6: 938-943.
6. Carmassi F, Morale M, Puccetti R, et al.: Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992, 67: 643-654.
7. Hseuh WA, Anderson PW: Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992, 20: 253-263.
8. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339: 229-234.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993, 329: 1456-1462.
10. Chatuverdi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351: 28-31.
11. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157: 2413-2446.
12. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999, 17: 151-183.
13. Ramsay LE, Williams B, Johnston GD, et al.: Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999, 13: 569-592.
14. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Efects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355: 253-259. Treatment with the ACE inhibitor ramipril reduces the risk of myocardial infarction, stroke, and cardiovascular death in diabetic patients with previous cardiovascular disease or associated cardiovascular risk factors.
15. Ruilope LM, García-Robles R: How far should blood pressure be reduced in diabetic hypertensive patients? J Hypertens 1997, 15(suppl 2): S63-S65.
16. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group: Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351: 1755-1762. Intensive blood pressure lowering with antihypertensive treatement based on the calcium channel blocker felodipine reduces major cardiovascular events and cardiovascular mortality in diabetic hypertensive patients.
17. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317: 703-712. Tight blood pressure control in hypertensive type 2 diabetics protects against diabetes-related macrovascular and microvascular complications.
18. Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276: 1886-1892.
19. Hansson L, Lindholm LH, Ekbom T, et al.: for the STOPHypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999, 354: 1751-1756. Conventional (diuretics and/or b-blockers) or new drugs (calcium antagonists or ACE inhibitors) are equally effective in preventing cardiovascular disease in elderly patients with hypertension.
20. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317: 713-720. Captopril and atenolol are equally effective in reducing diabetesrelated complications in type 2 diabetic hypertensive patients with tight blood pressure control (L 150/85)
21. Birkenhäger WH, Staessen JA: Treatment of diabetic patients with hypertension. Curr Hypertens Rep 1999, 1: 225-231.
22. Estacio RO, Jeffers BW, Hiatt WR, et al.: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338: 645-652.
23. Tatti P, Pahor M, Byington RP, et al.: Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21: 597-603.
24. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. for the Systolic Hypertension in Europe Trial Investigators: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340: 677-684. Post hoc analysis of the SYST-EUR trial comparing diabetic and nondiabetic patients with isolated systolic hypertension showing that nitrendipine-based treatment decreases cardiovascular mortality only in the subgroup of diabetics.
25. Hansson L, Lindholm LH, Niskanen L, et al., for the Captopril Prevention Project (CAPPP) Study Group: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353: 611-616. Captopril, compared with conventional therapy (diuretics and/or b-blockers), is more effective in decreasing the risk of myocardial infarction in hypertensive diabetic patients.
26. Burnier M, Rutschmann B, Nussberger J, et al.: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993, 22: 339-347.
27. Burnier M, Hagman B, Nussberger J, et al.: Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995, 25: 602-609.
28. Schmitt F, Natov S, Martinez F, et al.: Renal effects of angiotensin II receptor blockade and angiotensin convertase inhibition in man. Clin Sci 1996, 90: 205-213.
29. Price DA, De Oliveira JM, Fisher NDL, Hollenberg NK: Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy man. Hypertension 1997, 30: 240-246.
30. Doig JK, MacFadyen RJ, Sweet CS, Reid JL: Haemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol 1995, 25: 511-517.
31. Kawabata M, Takabatake T, Ohta H, et al.: Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension. Blood Press 1994, 5(suppl):117-121.
32. Erley CM, Bader B, Scheu M, et al.: Renal hemodynamics in essntial hypertensives treated with losartan. Clin Nephrol 1995, 43(suppl 1): S8-S11.
33. Fauvel JP, Velon S, Berra N, et al.: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996, 28: 259-263.
34. Nielsen S, Dollerup J, Nielsen B, et al.: Losartan reduces albuminuria in patients with essentil hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997, 12(suppl 2):19-23.
35. Chan JC, Critchley JA, Tomlinson B, et al.: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 1997, 17: 72-80.
36. Gansevoort RT, Sluiter W, Hemmelder MH, et al.: Antiproteinuric effect of blood pressure lowering angents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995, 10: 1963-1974.
37. Toto R, Shultz P, Raij L, et al.: Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998, 31: 684-691.
38. O'Donnell MP, Crary GS, Oda H, et al.: Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int 1997, 63(suppl): S218-S220.